Literature DB >> 29442260

Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.

Serena Vettori1, Salvatore Tolone2, Domenico Capocotta3, Rossella Chieffo3, Veronica Giacco3, Gabriele Valentini3, Ludovico Docimo2.   

Abstract

This study aims to investigate pre-clinical esophageal involvement in systemic sclerosis (SSc) by high-resolution impedance manometry (HRiM), its associations with disease features including lung involvement, and its predictivity of esophageal symptoms overtime. Charts of 45 asymptomatic (no heartburn/regurgitation/dysphagia) SSc patients (96% females; mean age 46 years) with at least one follow-up (FU) visit and complete clinical, serological, functional, and radiological assessment, including high-resolution computed tomography (HRCT) of the chest and lung function tests, that had undergone esophageal HRiM were retrospectively evaluated. Esophagogastric junction-contractile integral (EGJ-CI) and esophageal body motility, as evaluated by mean distal contractile integral (DCI), were assessed. SSc patients had a normal esophageal motility in 7/45 cases, a defective EGJ-CI in 28, an ineffective esophageal motility (IEM) in 17, and aperistalsis in 12. Defective EGJ-CI was associated with IEM/aperistalsis in 20 cases, while 9 patients had isolated IEM. Defective EGJ-CI and/or IEM/aperistalsis were associated with a diffusing lung capacity for CO < 80% of predicted value (all p < 0.05), while defective EGJ-CI was also associated with interstitial lung disease on HRCT (p = 0.03). Prevalence of any HRiM abnormality was higher in anti-centromere antibody negative patients (all p < 0.05). IEM/aperistalsis independently increased the risk of esophageal symptoms by 2.3-fold (95% CI 1.1-5.7) and was associated with their higher cumulative incidence with respect to patients with other HRiM patterns at FU (χ2 = 4.63; p = 0.03). SSc patients asymptomatic for esophageal involvement can have HRiM abnormalities in up to 84% of cases. A baseline-impaired motility is a risk factor for symptomatic esophageal disease.

Entities:  

Keywords:  Esophageal dysmotility; High-resolution manometry; Impedance; Preclinical esophageal involvement; Prediction; Systemic sclerosis

Mesh:

Year:  2018        PMID: 29442260     DOI: 10.1007/s10067-018-4026-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  41 in total

Review 1.  Gastrointestinal complications: the most frequent internal complications of systemic sclerosis.

Authors:  A Forbes; I Marie
Journal:  Rheumatology (Oxford)       Date:  2009-06       Impact factor: 7.580

Review 2.  New technologies in the gastrointestinal clinic and research: impedance and high-resolution manometry.

Authors:  John E Pandolfino; Peter J Kahrilas
Journal:  World J Gastroenterol       Date:  2009-01-14       Impact factor: 5.742

3.  Normal values for esophageal high-resolution manometry.

Authors:  A Bogte; A J Bredenoord; J Oors; P D Siersema; A J P M Smout
Journal:  Neurogastroenterol Motil       Date:  2013-06-12       Impact factor: 3.598

4.  The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters.

Authors:  J N Kimmel; D A Carlson; M Hinchcliff; M A Carns; K A Aren; J Lee; J E Pandolfino
Journal:  Neurogastroenterol Motil       Date:  2016-02-27       Impact factor: 3.598

5.  High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.

Authors:  Hanan Sayed M Abozaid; Hala M K Imam; Marwa Mahmoud Abdelaziz; Dina H El-Hammady; Nihal A Fathi; Daniel E Furst
Journal:  Semin Arthritis Rheum       Date:  2017-05-19       Impact factor: 5.532

6.  Detection of early asymptomatic esophageal dysfunction in systemic sclerosis using a new scintigraphic grading method.

Authors:  S A Kaye; Q H Siraj; J Agnew; A Hilson; C M Black
Journal:  J Rheumatol       Date:  1996-02       Impact factor: 4.666

7.  Esophageal involvement and pulmonary manifestations in systemic sclerosis.

Authors:  I Marie; S Dominique; H Levesque; P Ducrotté; P Denis; M F Hellot; H Courtois
Journal:  Arthritis Rheum       Date:  2001-08

8.  Esophageal disease in progressive systemic sclerosis.

Authors:  Ellen C Ebert
Journal:  Curr Treat Options Gastroenterol       Date:  2008-02

Review 9.  Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma).

Authors:  H Sallam; T A McNearney; J D Z Chen
Journal:  Aliment Pharmacol Ther       Date:  2006-03-15       Impact factor: 8.171

10.  Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.

Authors:  Florian M P Meier; Klaus W Frommer; Robert Dinser; Ulrich A Walker; Laszlo Czirjak; Christopher P Denton; Yannick Allanore; Oliver Distler; Gabriela Riemekasten; Gabriele Valentini; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2012-05-21       Impact factor: 19.103

View more
  5 in total

Review 1.  The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review.

Authors:  Wouter Schutyser; Ludovic Cruyt; Jean-Baptiste Vulsteke; Jan L Lenaerts; Ellen De Langhe
Journal:  Clin Rheumatol       Date:  2019-11-11       Impact factor: 2.980

Review 2.  GI Manifestations With a Focus on the Esophagus: Recent Progress in Understanding Pathogenesis.

Authors:  Marie-Pier Tétreault; Peter Kahrilas
Journal:  Curr Rheumatol Rep       Date:  2019-07-03       Impact factor: 4.592

3.  Esophageal Dilatation as a Predictor of Systemic Sclerosis in Patients with Interstitial Lung Disease.

Authors:  Ana Filipa Santos Duarte de Figueiredo; João Felício Costa; António P Matos; Miguel Ramalho
Journal:  Turk Thorac J       Date:  2021-05

Review 4.  Esophageal Dysfunction in Systemic Sclerosis: An Update.

Authors:  Bo Li; Junqing Yan; Jincheng Pu; Jianping Tang; Shuchang Xu; Xuan Wang
Journal:  Rheumatol Ther       Date:  2021-10-09

Review 5.  Esophageal manifestation in patients with scleroderma.

Authors:  Theodoros A Voulgaris; Georgios P Karamanolis
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.